Search results for "Azepines"

showing 10 items of 135 documents

Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.

2005

Summary Nocturnal hormone profiles were measured in patients with schizophrenia with predominantly negative symptoms both under drug-free baseline conditions and after subchronic administration of the atypical antipsychotic olanzapine, with the aim of characterizing its pharmacological properties on the neuroendocrine level. The following hormones were studied in the sleep laboratory under polysomnographic control: adrenocorticotrophic hormone, cortisol, growth hormone (GH), prolactin, testosterone, and melatonin. Blood samples were taken at regular time intervals over the night, and serum concentrations of the hormones were determined. Ten patients completed the study, two of them were exc…

OlanzapineAdultMalemedicine.medical_specialtyHydrocortisonemedicine.drug_classEndocrinology Diabetes and MetabolismAtypical antipsychoticMelatoninBenzodiazepinesEndocrinologyAdrenocorticotropic HormoneInternal medicinemedicineHumansTestosteroneCircadian rhythmBiological PsychiatryTestosteroneMelatoninInpatientsEndocrine and Autonomic SystemsDopamine antagonistProlactinCircadian RhythmProlactinPsychiatry and Mental healthEndocrinologyOlanzapineGrowth HormoneSchizophreniaPsychologySleepmedicine.drugHormoneAntipsychotic AgentsPsychoneuroendocrinology
researchProduct

Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.

2012

Abstract Background Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time. The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis. We aimed to investigate the effects of low doses of haloperidol, risperidone and olanzapine on cortical thickness. Method We investigated the effects of risperidone (N = 16), olanzapine (N = 18) and low doses of haloperidol (N = 18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients. The relationship between cortical thick…

OlanzapineAdultMalemedicine.medical_specialtyPsychosisAdolescentmedicine.medical_treatmentNeuropsychological TestsBenzodiazepinesYoung AdultDouble-Blind MethodInternal medicinemedicineHaloperidolImage Processing Computer-AssistedHumansAntipsychoticScale for the Assessment of Negative SymptomsBiological PsychiatryAgedRetrospective StudiesCerebral CortexPsychiatric Status Rating ScalesAnalysis of VarianceRisperidoneVoxel-based morphometryMiddle Agedmedicine.diseaseRisperidoneMagnetic Resonance ImagingPsychiatry and Mental healthEndocrinologyFrontal lobeOlanzapineSchizophreniaHaloperidolFemalePsychologyCognition Disordersmedicine.drugClinical psychologyAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-…

2016

ObjectivesTo meta-analytically summarize lamotrigine’s effectiveness and safety in unipolar and bipolar depression.MethodsWe conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs).ResultsEighteen studies (n=2152, duration=9.83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation …

Olanzapinemedicine.medical_specialtyBipolar DisorderLithium (medication)Bipolar depressionBipolar depression bipolar disorder lamotrigine major depressive disorder trials unipolar depressionCitalopramLithiumCitalopramLamotrigineLamotriginePlaceboBipolar depression; bipolar disorder; lamotrigine; major depressive disorder; trials; unipolar depressionBenzodiazepines03 medical and health sciences0302 clinical medicineAntimanic AgentsFluoxetineInternal medicinemedicineHumansBipolar disorderunipolar depressionPsychiatryDepressive Disorder MajorFluoxetinemajor depressive disorderDepressionTriazinesbusiness.industrytrialsmedicine.diseaseAntidepressive Agents030227 psychiatryDrug CombinationsPsychiatry and Mental healthVitamin B ComplexMajor depressive disorderAnticonvulsantsNeurology (clinical)businessInositol030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

The GiSAS study: Rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatme…

2011

Given the controversy about the comparative efficacy of first- compared with second-generation antipsychotics in the treatment of schizophrenia, more large-scale evidence is needed to guide clinicians in their prescriptions. Most randomized controlled trials (RCTs) were conducted in centers of excellence on highly selected samples, poorly representative of real-world patients, and often suffered conflicts of interest as they were sponsored by drug companies. The primary aim of the present study is to compare the effectiveness of haloperidol, olanzapine and aripiprazole in a representative sample of schizophrenia patients. The GiSAS trial is an open-label, independent, pragmatic RCT in Itali…

Olanzapinemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAripiprazoleQuinolonesPragmatic trialPiperazineslaw.inventionAntipsychoticBenzodiazepinesRandomized controlled triallawAntipsychotic; Pragmatic trial; SchizophreniamedicineClinical endpointHumansPharmacology (medical)AntipsychoticPsychiatrySettore MED/25 - PsichiatriaProportional Hazards Modelsbusiness.industryPatient SelectionGeneral MedicineDiscontinuationLogistic ModelsItalyTolerabilityOlanzapineResearch DesignSchizophreniaPhysical therapyHaloperidolObservational studyAripiprazoleantipsychotic schizophrenia metabolic syndromebusinessAntipsychotic Agentsmedicine.drugContemporary Clinical Trials
researchProduct

Effectiveness of Safety Warnings in Atypical Antipsychotic Drugs

2009

Studies conducted to obtain drug authorization are often of short duration and based on small sample sizes in selected populations. Policies on drug safety rely on the validity of the methods used to achieve rapid and effective communication of new information. No formal evaluation has ever been made of the Spanish communications system, although indirect data have raised questions about its effectiveness.To evaluate the impact of two safety warnings issued by the Spanish Drug Agency, and of a later prior authorization requirement involving the use of atypical antipsychotic drugs in the elderly.The study was based on a time-series analysis constructed with data corresponding to monthly invo…

Olanzapinemedicine.medical_specialtymedicine.drug_classAtypical antipsychoticToxicologyCommunications systemInterrupted Time Series AnalysisBenzodiazepinesmedicineHumansPharmacology (medical)ZiprasidoneAmisulpridePractice Patterns Physicians'Medical prescriptionPsychiatryAgedPharmacologyRisperidoneDose-Response Relationship DrugInformation Disseminationbusiness.industryRisperidonemedicine.diseaseOlanzapineSpainDrug and Narcotic ControlDementiaMedical emergencybusinessAntipsychotic Agentsmedicine.drugDrug Safety
researchProduct

Dual orexin receptor blocker suvorexant attenuates hypercapnic ventilatory augmentation in mice

2022

Suvorexant (Belsomra(R)), a dual orexin receptor antagonist widely used in the treatment of insomnia, inhibits the arousal system in the brain. However, the drug’s ventilatory effects have not been fully explored. This study aims to investigate the expression of orexin receptors in respiratory neurons and the effects of suvorexant on ventilation. Immunohistology of brainstem orexin receptor OX2R expression was performed in adult mice (n = 4) in (1) rostral ventral respiratory group (rVRG) neurons projecting to the phrenic nucleus (PhN) retrogradely labeled by Fluoro-Gold (FG) tracer, (2) neurons immunoreactive for paired like homeobox 2b (Phox2b) in the parafacial respiratory group/retrotra…

OrexinsGeneral NeuroscienceAzepinesCarbon DioxideReceptors Neurokinin-1TriazolesHypercapniaMiceOrexin ReceptorsAnimalsOrexin Receptor AntagonistsNeurology (clinical)SomatostatinMolecular BiologyTranscription FactorsDevelopmental BiologyBrain Research
researchProduct

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

2021

Recently, the first squaramide-(SA) containing FAP inhibitor-derived radiotracers were introduced. DATA5m.SA.FAPi and DOTA.SA.FAPi with their non-radioactive complexes showed high affinity and selectivity for FAP. After a successful preclinical study with [68Ga]Ga-DOTA.SA.FAPi, the first patient studies were realized for both compounds. Here, we present a new squaramide-containing compound targeting FAP, based on the AAZTA5 chelator 1,4-bis-(carboxylmethyl)-6-[bis-(carboxymethyl)-amino-6-pentanoic-acid]-perhydro-1,4-diazepine. For this molecule (AAZTA5.SA.FAPi), complexation with radionuclides such as gallium-68, scandium-44, and lutetium-177 was investigated, and the in vitro properties of…

PREPPharmaceutical ScienceAcetatesLutetiumLigands030218 nuclear medicine & medical imagingAnalytical ChemistrySerinechemistry.chemical_compoundQD241-4410302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographyDrug Discoverylutetium-177AAZTA; scandium-44; lutetium-177; FAP; SA; DPP; PREPQuinineChemistrySerine EndopeptidasesAzepinesscandium-44ChemistryChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineSelectivityDPPGallium RadioisotopesConjugated systemArticleHeterocyclic Compounds 1-Ring03 medical and health sciencesSAEndopeptidasesHumansDOTAChelationPhysical and Theoretical ChemistryBiologyAAZTARadioisotopesOrganic ChemistrySquaramideMembrane ProteinsFAPFibroblastsCombinatorial chemistryIn vitroRadiopharmaceuticalsScandiumMolecules
researchProduct

Pesticide residues in Lake Albufera, Valencia, Spain.

1987

Abstract Analysis of water samples from the lake in Albufera, Valencia, indicates that the pesticides molinate, benthiocarb, and fenitrothion do not reach levels that are lethal to fish.

Pesticide residuebiologyHerbicidesFishesPesticide ResiduesGeneral ChemistryAzepinesFenitrothionPesticidebiology.organism_classificationFenitrothionchemistry.chemical_compoundchemistryEnvironmental protectionSpainThiocarbamatesEnvironmental chemistryFish <Actinopterygii>AnimalsWater PollutantsValenciaBenthiocarbWater Pollutants ChemicalJournal - Association of Official Analytical Chemists
researchProduct

Interactions of benzodiazepines with human serum albumin. Circular dichroism studies.

1973

The circular dichroism spectra of 12 benzodiazepine derivatives studied in presence of human serum albumin are presented. Nearly all substances give biphasic extrinsic Cotton effects. At the CD maxima the molar ellipticities and the anisotropy factors are calculated. The influence of the chemical structure of the benzodiazepines on the induced Cotton effect is discussed. There is a linear correlation between the anisotropy factors and the logarithms of the partition coefficients of the substances. It is suggested that the phenyl ring of the benzodiazepine molecule is one of the essential groups for the binding of these substances to human serum albumin.

PharmacologyBenzodiazepineCircular dichroismChromatographyBinding SitesChemistrymedicine.drug_classChemical structureCircular DichroismGeneral MedicineBenzazepinesHuman serum albuminCircular dichroism spectraPartition coefficientStructure-Activity RelationshipOptical Rotatory DispersionmedicineMoleculeHumansSpectrophotometry UltravioletChlorineCotton effectSerum Albuminmedicine.drugProtein BindingNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Insight on pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepine systems as promising photosensitizers on malignant cells

2022

Searching for new small molecules as photosensitizing agents, we have developed a class of twenty-five pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepines with a good substitution pattern defining a versatile synthetic pathway to approach the title ring system. All compounds were evaluated for their photocytotoxicity on a triple negative human breast cancer cell line (MDA-MB-231) in the dark and under UVA light (2.0 J/cm2). The most effective compounds exhibited a photoantiproliferative activity with IC50 values up to nanomolar ranges. Interestingly, these new developed compounds showed high selectivity towards cancerous cells with respect to non-cancerous ones. Moreover, fo…

PharmacologyMDA-MB-231Triple negative human breast cancerOrganic ChemistryPhototoxic activityIndolizinesAntineoplastic AgentsApoptosisTriple Negative Breast Neoplasms4-g]indolizinespyrimido[4General MedicineAzepinespyrimido[54-g]indolizinespyrimido[45-c]pyrrolo[12-a]azepinesTriple negative human breast cancerMDA-MB-231Photosensitizing agentsPhototoxic activitypyrimido[5Photosensitizing agents5-c]pyrrolo[1pyrimido[45-c]pyrrolo[12-a]azepinesCell Line Tumor2-a]azepinesTriple negative human breast cancerMDA-MB-231Photosensitizing agentsPhototoxic activityDrug DiscoveryHumanspyrimido[54-g]indolizines
researchProduct